11:22 AM EDT, 05/28/2024 (MT Newswires) -- CorMedix ( CRMD ) shares rose 4.3% in recent Tuesday trading after the company said it will supply its DefenCath product to an undisclosed "top-tier midsized" dialysis provider under a multiyear commercial contract.

The company commercially launched DefenCath in inpatient settings in April and plans to expand to outpatient settings in July. CorMedix ( CRMD ) said it also plans to develop DefenCath as a catheter lock solution for use in other patient populations.

Price: 5.34, Change: +0.22, Percent Change: +4.30